Eli Lilly is a global pharmaceutical company headquartered in Indianapolis that combines internal R&D with strategic investment activity across healthcare and biotechnology. Its interest in precision neuroscience and digitally enabled health innovation makes it relevant beyond traditional pharmaceuticals.

The company has backed businesses working in areas such as precision psychiatry, AI-enabled diagnostics, and neurodegenerative disease tools. Lilly is particularly valuable where a startup’s platform intersects with clinical development, biomarker-driven neuroscience, or data-rich mental health innovation.

Its innovation reach is global, with strong activity in the United States and major biotech centers. For neurotech founders, Lilly is most relevant as a strategic investor or partner where the product has translational clinical significance and could integrate into therapeutic development or healthcare delivery.